Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6

• Status: Completed
• Trial end date: 2012-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety, tolerability, and efficacy of sofosbuvir (GS-7977; PSI-7977) administered in combination with pegylated interferon and ribavirin (PEG/RBV) in treatment-naive patients with HCV genotypes 1,4,5,6, or indeterminate genotype.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gilead Sciences
• Treatments: Interferons; Ribavirin; Sofosbuvir

Criteria

Inclusion Criteria:

• Males and females with Chronic Hepatitis C (HCV) Genotype 1,4,5,6, or indeterminate

• Naive to previous HCV treatment

Exclusion Criteria:

• Positive for HBsAg, anti-HBc IgM Ab, or anti-HIV Ab

• History of any other clinically significant chronic liver disease